Rating on Mallinckrodt (NYSE:MNK) is Neutral. Its Reiterates by B. Riley FBR with $20 Target.

June 29, 2018 - By Daniel Mitchell

Big Money Sentiment increased to 0.9 in 2018 Q1. It has change of 0.19, from 2017Q4’s 0.71. The ratio increased due to Mallinckrodt Public Limited Company positioning: 38 sold and 85 reduced. 47 funds bought positions and 64 increased positions. Investors holded 90.73 million in 2017Q4 but now own 96.44 million shares or 6.30% more.

Smithfield owns 37 shs or 0% of their US capital. Oregon Public Employees Retirement Fund holds 0.01% or 35,755 shs. First Foundation holds 0.07% or 90,046 shs in its capital. Point72 Asia (Hong Kong) invested in 0.02% or 2,671 shs. Moreover, Louisiana State Employees Retirement Systems has 0.02% invested in Mallinckrodt Public Limited Company (NYSE:MNK). Canada Pension Plan Invest Board owns 206,110 shs. Commonwealth Financial Bank Of Aus has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Cwm Ltd Liability Corp holds 0% of its capital in Mallinckrodt Public Limited Company (NYSE:MNK) for 430 shs. Savings Bank Of Mellon Corporation owns 1.06M shs for 0% of their capital. State Of New Jersey Common Pension Fund D reported 640,000 shs. Advisory Svcs Network Limited Com accumulated 66 shs or 0% of the stock. Enterprise Financial Service reported 114 shs or 0% of all its holdings. Riverhead Cap Mgmt Limited Liability has 5,266 shs. Susquehanna Grp Limited Liability Partnership accumulated 303,812 shs. Dreman Value Management L L C accumulated 0% or 84 shs.

Mallinckrodt Public Limited Company had 1 insider sale and 1 buying transaction since May 9, 2018. This’s net activity of $4.14 million. $4.19M worth of Mallinckrodt Public Limited Company (NYSE:MNK) was sold by Flynn James E on Wednesday, May 9.

Reiterated Mallinckrodt (NYSE:MNK) Rating.

On Thursday, 28 June a note was released on Mallinckrodt (NYSE:MNK) of its Neutral Rating reaffirmed by expert analysts at B. Riley FBR. The market cap company was given $20 PT that indicates 7.18 % upside potential from the last price.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Coverage

A total of 12 analysts rate Mallinckrodt (NYSE:MNK) as follows: 4 “Buy”, 7 “Hold” and 1 “Sell”. Тherefore 33% are bullish. (NYSE:MNK) has 22 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Tuesday, January 9 the stock of Mallinckrodt Public Limited Company (NYSE:MNK) has “Hold” rating given by Mizuho. On Thursday, April 26 the rating was maintained by Mizuho with “Hold”. On Tuesday, February 6 the rating was maintained by BMO Capital Markets with “Buy”. On Friday, April 20 the rating was maintained by Mizuho with “Hold”. The stock rating was maintained by Piper Jaffray with “Buy” on Tuesday, January 2. On Monday, April 23 the company was maintained by Leerink Swann. On Tuesday, March 6 Canaccord Genuity maintained Mallinckrodt Public Limited Company (NYSE:MNK) rating. Canaccord Genuity has “Hold” rating and $20.0 target. The company rating was downgraded by Barclays Capital on Friday, February 2. On Wednesday, May 9 Morgan Stanley maintained Mallinckrodt Public Limited Company (NYSE:MNK) with “Equal-Weight” rating. In Tuesday, February 27 report Mizuho maintained it with “Hold” rating and $21.0 target.

MNK hit $18.66 during the last trading session after $0.52 change.Currently Mallinckrodt Public Limited Company is downtrending after 59.76% change in last June 29, 2017. MNK has also 1.25 million shares volume. The stock underperformed the S&P500 by 72.33%.

Earnings report for Mallinckrodt Public Limited Company (NYSE:MNK) is awaited on August, 14., according to Zacks. earnings per share of $1.49 is 19.46 % down from 2017’s $1.85 EPS. If $1.49 is reported, MNK’s profit will be $123.77 million for 3.13 P/E. Wall Street now forecasts 13.74 % EPS growth despite Mallinckrodt Public Limited Company previous quarter’s EPS of $1.31.

Mallinckrodt public limited company develops, makes, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions.The company has $1.55 billion market cap. The firm markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.1.02 is the P/E ratio. It offers H.P.

More recent Mallinckrodt Public Limited Company (NYSE:MNK) news were announced by Seekingalpha.com, Streetinsider.com and Streetinsider.com. The first one has “Mallinckrodt: The Cheapest Stock In Global Healthcare” as a title and was announced on June 08, 2018. The next is “Aurobindo Said in Advanced Talks to buy Mallinckrodt’s (MNK) Specialty Generics Business – CNBC-TV18” on June 28, 2018. And last was announced on June 28, 2018, called “Mallinckrodt (MNK) Reports Complete Enrollment Target for Rheumatoid Arthritis Phase 4 Clinical Study for HP Acthar …”.

Mallinckrodt Public Limited Company (NYSE:MNK) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: